Insights

Gathering insights about UTIL…

Similar companies to UTIL

UTIL Tech Stack

UTIL uses 8 technology products and services including jsDelivr, WordPress, oEmbed, and more. Explore UTIL's tech stack below.

jsDelivr
Content Delivery Network
WordPress
Content Management System
oEmbed
Dev Tools
jQuery
Javascript Libraries
Slider Revolution
Miscellaneous
Yoast SEO
Search Engines
Contact Form 7
Web Platform Extensions
Magnific Popup
Web Tools And Plugins

Media & News

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefining Proteomics with Single-Molecule Iterative Mapping” on November 10
Nov 03, 2025 | www.globenewswire.com
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ -- NewcelX Ltd.
Oct 30, 2025 | www.prnewswire.com
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection.
Oct 30, 2025 | www.prnewswire.com
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd.
Oct 29, 2025 | www.prnewswire.com
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's issued and outstanding common shares, par value CHF 0.03 per share (the "Common Shares"), at a ratio of 1-for-10 (the "Reverse Split").
Oct 29, 2025 | www.prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd.
Oct 29, 2025 | www.prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel , Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd.
Oct 27, 2025 | www.prnewswire.com

UTIL's Email Address Formats

UTIL uses at least 1 format(s):

UTIL Email Formats	Example	Percentage
First.Last@utilgroup.com	John.Doe@utilgroup.com	85%
FiLast@utilgroup.com	JoDoe@utilgroup.com	6%
L.First@utilgroup.com	D.John@utilgroup.com	5%
LastFi@utilgroup.com	DoeJo@utilgroup.com	4%

Frequently Asked Questions

Where is UTIL's headquarters located?

UTIL's main headquarters is located at Via Giovanni XXIII, 10, Villanova d'Asti, Asti 14019, IT. The company has employees across 5 continents, including EuropeNorth AmericaSouth America.

What is UTIL's phone number?

You can contact UTIL's main corporate office by phone at

+39-0141-94****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is UTIL's stock symbol?

UTIL is a publicly traded company; the company's stock symbol is NLS.

What is UTIL's official website and social media links?

UTIL's official website is utilgroup.com and has social profiles on LinkedIn.

What is UTIL's NAICS code?

UTIL's NAICS code is 3363 - Motor Vehicle Parts Manufacturing.

How many employees does UTIL have currently?

As of October 2025, UTIL has approximately 227 employees across 5 continents, including EuropeNorth AmericaSouth America. Key team members include Chief Executive Officer: M. T.Group Cfo: E. G.President Of Asia: A. L.. Explore UTIL's employee directory with LeadIQ.

What industry does UTIL belong to?

UTIL operates in the Motor Vehicle Parts Manufacturing industry.

What technology does UTIL use?

UTIL's tech stack includes jsDelivrWordPressoEmbedjQuerySlider RevolutionYoast SEOContact Form 7Magnific Popup.

What is UTIL's email format?

UTIL's email format typically follows the pattern of First.Last@utilgroup.com. Find more UTIL email formats with LeadIQ.

When was UTIL founded?

UTIL was founded in 1959.

UTIL

Motor Vehicle Parts ManufacturingItaly201-500 Employees

UTIL was founded in 1959 and rapidly became a go-to company for the production of parts for brake systems for the automotive sector, earning a significant share of the global market.

In 2019, we embarked on an extensive project to diversify our portfolio of solutions, developing technology and innovative products for other sectors, such as agricultural and earthmoving machines, construction, household appliances, electrical mobility and mobility on two wheels.

We now have manufacturing facilities and research centers in Italy and China and commercial offices in Germany and the United States.

Company Overview

Headquarters: Via Giovanni XXIII, 10, Villanova d'Asti, Asti 14019, IT
Phone number: +39-0141-94****
Website: utilgroup.com
Stock Symbol: NLS
NAICS Code: 3363 - Motor Vehicle Parts Manufacturing
Founded: 1959
Employees: 201-500

Media & News

Funding & Financials

$100M$250M
UTIL's revenue is estimated to be in the range of $100M$250M

Funding & Financials

$100M$250M
UTIL's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to UTIL

Guanabara

Cometa

UTIL Tech Stack

Media & News

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

UTIL's Email Address Formats

Frequently Asked Questions

Where is UTIL's headquarters located?

What is UTIL's phone number?

What is UTIL's stock symbol?

What is UTIL's official website and social media links?

What is UTIL's NAICS code?

How many employees does UTIL have currently?

What industry does UTIL belong to?

What technology does UTIL use?

What is UTIL's email format?

When was UTIL founded?

UTIL

Company Overview

Media & News

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?